Trial · NCT03417245
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period | Factor On-demand | 30.991 | 95% Confidence Interval 21.114 to 45.487 | episodes per participant per year | |
| Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period | Fitusiran 80 mg Prophylaxis | 3.133 | 95% Confidence Interval 2.269 to 4.326 | episodes per participant per year | |
| Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period | Factor On-demand | 21.8 | Inter-Quartile Range 8.4 to 41.0 | episodes per participant per year | |
| Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period | Fitusiran 80 mg Prophylaxis | 0.0 | Inter-Quartile Range 0.0 to 3.4 | episodes per participant per year | |
| Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period | Factor On-demand | 31.444 | 95% Confidence Interval 22.995 to 42.999 | episodes per participant per year | |
| Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period | Fitusiran 80 mg Prophylaxis | 4.092 | 95% Confidence Interval 3.143 to 5.328 | episodes per participant per year | |
| Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period | Factor On-demand | 25.2 | Inter-Quartile Range 11.9 to 43.8 | episodes per participant per year | |
| Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period | Fitusiran 80 mg Prophylaxis | 1.8 | Inter-Quartile Range 0.0 to 4.5 | episodes per participant per year | |
| Estimated Annualized Spontaneous Bleeding Rate for Treated Bleeds During the Efficacy Period | Factor On-demand | 22.036 | 95% Confidence Interval 14.159 to 34.295 | episodes per participant per year | |
| Estimated Annualized Spontaneous Bleeding Rate for Treated Bleeds During the Efficacy Period | Fitusiran 80 mg Prophylaxis | 1.825 | 95% Confidence Interval 1.237 to 2.692 | episodes per participant per year | |
| Observed Annualized Spontaneous Bleeding Rate for Treated Bleeds During the Efficacy Period | Factor On-demand | 16.1 | Inter-Quartile Range 3.4 to 27.6 | episodes per participant per year | |
| Observed Annualized Spontaneous Bleeding Rate for Treated Bleeds During the Efficacy Period | Fitusiran 80 mg Prophylaxis | 0.0 | Inter-Quartile Range 0.0 to 1.7 | episodes per participant per year | |
| Estimated Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period | Factor On-demand | 23.413 | 95% Confidence Interval 15.363 to 35.680 | episodes per participant per year | |
| Estimated Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period | Fitusiran 80 mg Prophylaxis | 2.282 | 95% Confidence Interval 1.594 to 3.268 | episodes per participant per year | |
| Observed Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period | Factor On-demand | 15.9 | Inter-Quartile Range 4.2 to 33.5 | episodes per participant per year | |
| Observed Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period | Fitusiran 80 mg Prophylaxis | 0.0 | Inter-Quartile Range 0.0 to 3.4 | episodes per participant per year | |
| Health-related Quality of Life (HRQOL): Change From Baseline in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Score at Month 9 | Factor On-demand | -3.32 | 95% Confidence Interval -9.67 to 3.04 | scores on a scale | |
| Health-related Quality of Life (HRQOL): Change From Baseline in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Score at Month 9 | Fitusiran 80 mg Prophylaxis | -23.07 | 95% Confidence Interval -28.00 to -18.14 | scores on a scale | |
| Health-related Quality of Life (HRQOL): Change From Baseline in Haem-A-QOL Total Score at Month 9 | Factor On-demand | -2.62 | 95% Confidence Interval -6.27 to 1.03 | scores on a scale | |
| Health-related Quality of Life (HRQOL): Change From Baseline in Haem-A-QOL Total Score at Month 9 | Fitusiran 80 mg Prophylaxis | -9.68 | 95% Confidence Interval -12.51 to -6.86 | scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03417245/results